Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
No trials found
News
NRX-101 Shows Promise as First Antidepressant to Reduce Suicidality in Bipolar Depression
NRx Pharmaceuticals completed enrollment of 74 patients in its Phase 2b/3 trial of NRX-101, a combination of D-cycloserine and lurasidone for treating suicidal treatment-resistant bipolar depression.